biomedcentral – Page 3 – Retraction Watch

NIH neuroscientist up to 16 retractions

Neuroscientist Stanley Rapoport just can’t catch a break.

Rapoport, who’s based at National Institute on Aging, is continuing to experience fallout from his research collaborations, after multiple co-authors have been found to have committed misconduct.

Most recently, Rapoport has had four papers retracted in three journals, citing falsified data in a range of figures. Although the notices do not specify how the data falsification occurred, Jagadeesh Rao, who was recently found guilty of research misconduct, is corresponding author on all four papers.

Back in December, Rapoport told us that a “number of retractions [for] Rao are still in the works:” Continue reading NIH neuroscientist up to 16 retractions

Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

Over the decades, the concept of peer review has changed dramatically – so what does the future hold? That’s a question examined in a new report issued today by BioMed Central and Digital Science, based on discussions held during the SpotOn London conference. (Disclosure: Our co-founder Ivan Oransky spoke there.) We spoke with Elizabeth Moylan, Senior Editor Research Integrity at BioMed Central, and Rachel Burley, Publishing Director at BioMed Central about the central question posed by the report: What will peer review look like in the year 2030?

Retraction Watch: People have many complaints about peer review. What do you think are its most pressing flaws?

Continue reading Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

Authors retract paper lacking approval to study asthma in athletes

The authors of a 2014 study about asthma in Norwegian athletes have retracted it after realizing they hadn’t obtained proper approval from an ethical committee.

The study’s first and corresponding author of the study in the British Journal of Sports Medicine — Julie Stang from the Norwegian School of Sports Sciences in Oslo — told us the authors had struggled to obtain ethical approval for the research, but believed the issue had been resolved.

However, earlier this year, a member of an ethical committee wrote an article in the Norwegian press about his concerns regarding the study, which tested the effects of three drugs on top athletes’ breathing. In it, he said the Regional Committees for medical and health professional research ethics (REC) had not approved the study, as members were concerned the presumably healthy athletes were being exposed to drugs used to treat asthma, which could enhance their performance.

Stang has denied that the study had anything to do with boosting athletic performance.

Stein Evensen, the committee member who wrote the article, declined to comment beyond the published text. So we’ve gotten the kronikk article translated from Norwegian using One Hour Translation. It reads: Continue reading Authors retract paper lacking approval to study asthma in athletes

Authors pull two papers about faulty glucose meters after industry prompts

Two papers evaluating glucose meters — used by diabetics to monitor blood sugar levels — suggested that a couple of the devices don’t work as well as they should. Perhaps unsurprisingly, the companies that sell those meters objected to how the studies were conducted. By all accounts, the companies appear to be justified in their complaints.

In both cases, researchers used blood drawn from veins to test the meters. But manufacturers of the WaveSense JAZZ and GlucoRx glucose meters said their devices are designed to work with fresh blood from a finger-prick. Both papers have now been retracted.

The retraction notice for “Technical and clinical accuracy of five blood glucose meters: clinical impact assessment using error grid analysis and insulin sliding scales,” published in 2015 in the Journal of Clinical Pathology, hints at the issue:

Continue reading Authors pull two papers about faulty glucose meters after industry prompts

How fake peer review happens: An impersonated reviewer speaks

Earlier this month, BioMed Central and Springer announced that they were retracting nearly 60 papers for a host of related issues, including manipulating the peer-review process. Recently, we were contacted by one of the reviewers who was impersonated by some of the authors of the retracted papers.

The scientist wants to remain anonymous, but provided us with emails that supported his version of events.

In case you need a refresher on the “events” that took place: The two publishers recently pulled 58 papers from authors mostly based in Iran, citing evidence of plagiarism, and manipulating the peer-review process and allocating authorship positions inappropriately.

It all started with a seemingly simple question, the scientist told us: Continue reading How fake peer review happens: An impersonated reviewer speaks

Medical journal retracts study over fake review, authorship concerns

A journal has retracted a 2015 study about lung cancer after learning the peer-review process had been compromised.

The paper was published in March, 2015 — the same month publisher BioMed Central (BMC) pulled 43 papers for fake reviews.

According to the retraction notice in the European Journal of Medical Research, the authors’ institution in China informed the publisher that the authors had used a third party to help with copyediting and submission to the journal, raising concerns about the authorship of the paper.

Here’s the retraction notice, published in August: Continue reading Medical journal retracts study over fake review, authorship concerns

Springer, BMC retracting nearly 60 papers for fake reviews and other issues

In a massive cleanup, Springer and BioMed Central announced today they are retracting 58 papers for several reasons, including manipulation of the peer-review process and inappropriately allocating authorship.

The papers appeared in seven journals, and more are under investigation.

In a release issued today, the publishers note: Continue reading Springer, BMC retracting nearly 60 papers for fake reviews and other issues

Despite retraction, antipsychotics still effective, safe for dementia, says author

Researchers have retracted a systematic review that suggested that antipsychotic drugs are effective and safe for patients with symptoms of dementia — but claim their re-analysis of the updated data still comes to the same conclusions.

According to the retraction notice in Alzheimer’s Research and Therapy, some participants were incorrectly included twice in the meta-analysis.

The corresponding authors recently lost another paper for an entirely different reason — earlier this year, we reported on a retraction in Annals of Neurology for Jin-Tai Yu and Lan Tan, affiliated with the Ocean University of China, Qingdao University, and Nanjing Medical University in China. The authors pulled that paper after appearing to pass off others’ data as their own.

Here’s the retraction notice for the review, issued earlier this year: Continue reading Despite retraction, antipsychotics still effective, safe for dementia, says author